The GREENFUND - we're buying the dip, big time, and here's why., page-58

"they could not outsource to just one provider and had to outsource to various suppliers, with the end result being 11 different batches produced for the purposes of the US study."
The idea that a number of different suppliers all somehow managed to get the BTX1503 into the all of the "placebo" vehicle is not logical. For the placebo vehicle to have statistically the same effect as the BTX1503, all of the placebo vehicle batches would have to contain BTX1503, otherwise if some of the placebo vehicle batches did not contain BTX1503, then there should have been some difference in the results when compared to the vehicle batches that were meant to contain BTX1503.
There is no plausible explanation for what happened in the US that will be fixed by using a new supplier. The only plausible explanation is that the BTX1503 works - as very clearly evidenced in the Australian trials but also the placebo worked just as well in the US.
My brother came up with a possible explanation. US citizens believe in their drugs. They take drugs for anything and everything. Perhaps with something like acne (as opposed to say cancer or heart disease), the placebo effect is very effective - just as effective as the BTX1503.
As dumb as this theory sounds, it is the only thing that actually makes any sense at this stage.
The problem; Assuming phase three goes ahead and the placebo effect is repeated in the US, can the FDA approve the BTX1503 if again there is no statistical difference between it and the placebo? If it is a placebo effect, hopefully a much larger phase three trial shows more differentiation and statistical difference.
One problem with this theory is that if the placebo effect is that strong for acne trials, why didn't the same thing happen with the two previously approved competitors drugs? So this is probably not the correct reason for the results either, but to me, it's more plausible than anything else put forward on this forum or the explanation provided by the company.
On the one hand, this seems like a very good buying or at least trading opportunity due to the performance of the BTX1503 and the very clear results in Australia but it's damned hard to buy something that has had the most bizarre phase two results that I have EVER seen and with the most bizarre excuse for those results.